The published safety and immunogenicity results from this trial are discussed below [48]. Extension of

recommendations and public financing to include vaccination of mid-adult women is debatable, based on the trial results and current knowledge of the epidemiology of genital HPV infection [49]. In most populations, immunity to vaccine-related types is expected to increase with age while the rates of incident infection, and the probability of infection progressing to cervical cancer, are expected to decrease. Consequently, cost modeling studies selleck products have indicated that vaccination becomes less cost effective with increasing age [50]. Interestingly, both vaccines are licensed by the European Medicines Agency (EMA) for use from the age of 9 onwards, but neither is licensed for women over age 26 in the U.S. However, the vaccines are not routinely provided to mid-adult women in publically financed programs in Europe. Nevertheless, it is clear Selleck HKI 272 from the trials that

some mid-adult women could potentially benefit from the vaccine, and it seems reasonable to permit them to purchase it on an individual basis. However vaccination cannot replace screening in mid-adult women. The efficacy of Gardasil® was examined in a placebo-controlled, double-blind trial in 4065 men ages 16–26 from 18 countries [51]. The primary endpoint of the study was protection from HPV6, 11, 16 or 18-associated incident EGLs, defined as external genital warts (condylomata acuminata) or penile, perianal or perineal intraepithelial neoplasia (PIN) of any grade, or cancer at these sites. Protection against this

combined endpoint was 90.4% in the ATP population and 65.5% in the ITT population. Of the EGLs, 28 of 31 and 72 of 77 were genital warts in the ATP and ITT cohorts, respectively, and most were associated with HPV6 or HPV11 infections. Significant protection against EGLs was also observed in both populations, irrespective of the HPV type in the lesion (Table 10), reflecting the large proportion of genital warts caused by the vaccine types 6 and 11. Similar efficacy against persistent infection endpoints was reported in the ATP analysis (Table 10). The results of this study have led to the licensure of Gardasil® for the prevention of EGL in men Mephenoxalone in several countries. A subset of 602 men in the above trial who reported having sex with men was concurrently enrolled in a study of anal infection and anal intraepithelial neoplasia (AIN). After 3 years, Gardasil® was 78.6% (95% CI: -0.4–97.7) effective against HPV16/18 (the two types that cause most anal cancers) and 77.5% (95% CI: 39.6–93.3) effective at preventing HPV6/11/16/18-related AIN of any grade in the ATP population. It was 54.9% (95% CI: 8.4–79.1) effective for preventing AIN of any grade caused by any HPV type [52]. Efficacy against AIN2+ for this population was 74.9% (95% CI: 8.8–95.4). An efficacy of 94.9% (95% CI: 80.4–99.4) was observed against persistent infection by the vaccine-targeted types.